BR9915820A - Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação - Google Patents

Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação

Info

Publication number
BR9915820A
BR9915820A BR9915820-5A BR9915820A BR9915820A BR 9915820 A BR9915820 A BR 9915820A BR 9915820 A BR9915820 A BR 9915820A BR 9915820 A BR9915820 A BR 9915820A
Authority
BR
Brazil
Prior art keywords
oxytocin
uterine contractions
agents
conjunction
clinical use
Prior art date
Application number
BR9915820-5A
Other languages
English (en)
Inventor
John A Copland Iii
Kirk L Ives
Melvyn Soloff
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR9915820A publication Critical patent/BR9915820A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Patente de Invenção: "USO CLìNICO DE TIAZOLIDINADIONASSOZINHAS OU EM CONJUNTO COM OUTROS AGENTES PARABLOQUEAR AS AçõES MEDIADAS PELA OXITOCINA, TALCOMO CONTRAçõES UTERINAS EM PARTO PREMATURO OULACTAçãO". A presente invenção fornece métodos de prevenirou reduzir a ação mediada pela oxitocina empregando-se umatiazolidinadiona, tal como troglitazona, ou compostos tipotiazolidinadiona. Estes métodos descrevem o emprego destescompostos sozinhos ou em combinação com pelo menos um outroagente, tal como um agente tocolítico. Isto oferece um novoregime terapêutico para o tratamento de ações mediadas pelaoxitocina, por exemplo indução de contrações uterinas, liberaçãode prostagiandina, e enfraquecimento do leite. Portanto, ascondições tais como parto prematuro e parto antes da liberação deCesareana podem ser tratadas por estes métodos.
BR9915820-5A 1998-10-29 1999-10-29 Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação BR9915820A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10613398P 1998-10-29 1998-10-29
PCT/US1999/025433 WO2000025781A1 (en) 1998-10-29 1999-10-29 Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation

Publications (1)

Publication Number Publication Date
BR9915820A true BR9915820A (pt) 2001-10-30

Family

ID=22309672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915820-5A BR9915820A (pt) 1998-10-29 1999-10-29 Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação

Country Status (19)

Country Link
US (1) US7528133B1 (pt)
EP (1) EP1126844A1 (pt)
JP (1) JP2002528500A (pt)
KR (1) KR20010089381A (pt)
CN (1) CN1328456A (pt)
AU (1) AU1330800A (pt)
BR (1) BR9915820A (pt)
CA (1) CA2348910A1 (pt)
CZ (1) CZ20011524A3 (pt)
HK (1) HK1041213A1 (pt)
HU (1) HUP0104900A3 (pt)
ID (1) ID29352A (pt)
IL (1) IL142841A0 (pt)
MX (1) MXPA01004257A (pt)
NO (1) NO20012090L (pt)
PL (1) PL347508A1 (pt)
TR (1) TR200101882T2 (pt)
WO (1) WO2000025781A1 (pt)
ZA (1) ZA200103999B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062563A2 (en) * 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
US10555934B2 (en) * 2016-01-04 2020-02-11 ObsEva S.A. Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ, インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
EP0844997A1 (en) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
TR200101882T2 (tr) 2001-12-21
US7528133B1 (en) 2009-05-05
KR20010089381A (ko) 2001-10-06
HUP0104900A2 (hu) 2002-04-29
NO20012090D0 (no) 2001-04-27
HUP0104900A3 (en) 2003-02-28
CN1328456A (zh) 2001-12-26
PL347508A1 (en) 2002-04-08
CZ20011524A3 (cs) 2002-01-16
EP1126844A1 (en) 2001-08-29
ZA200103999B (en) 2002-08-16
IL142841A0 (en) 2002-03-10
CA2348910A1 (en) 2000-05-11
JP2002528500A (ja) 2002-09-03
AU1330800A (en) 2000-05-22
ID29352A (id) 2001-08-23
MXPA01004257A (es) 2002-06-21
HK1041213A1 (zh) 2002-07-05
NO20012090L (no) 2001-06-27
WO2000025781A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
HU0004347D0 (pt)
BR0014512A (pt) Tratamento tópico para infecções por estreptococos
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
AR048324A1 (es) Metodos para tratar infecciones por vih
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
ATE362348T1 (de) System für die kontrollierte abgabe von aktiven materialien an eine zahnoberfläche
BR9915820A (pt) Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação
SI2219031T1 (sl) Uporaba leptina za zdravljenje lipoatrofije pri ljudeh in metoda za ugotavljanje dovzetnosti za navedeno zdravljenje
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
Hutchins Jr Myomectomy after selective preoperative treatment with a gonadotropin releasing hormone analog.
Dobbins et al. Conception rates after altered timing of AI associated with the CO-Synch+ CIDR protocol.
BR0015329A (pt) Uso de óxido nìtrico para o tratamento de constrição das vias aéreas
MD186C2 (ro) Metodă de tratament al endometritei după operaţia cezariană
IT1291307B1 (it) Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
RU94020412A (ru) Способ разворота плода
胡智慧 et al. Study on the Interrelation between Auricular Good Conduction Point Stimulation and the Therapeutic Effect
沈钦彦 Clinical Observation on Treatment of 89 Cases of Urine Retention with Acupuncture
Mathlouthi et al. Cervical ripening at term. A randomized and prospective study: Misoprotol versus dinoprostone
李佶 et al. Clinical Observation on Treatment of Endometriosis by Tonifying Qi and Promoting Blood Circulation to Remove Stasis and Purgation Principle
Greenhill Significance of achylic chloranemia (essential hypochromic anemia) in gynecology| Hildebrandt: Arch. f. Gynäk. 165: 164, 1937
UA30550A (uk) Спосіб лікування неплідності у жінок з гіперпролактинемією
UA37509A (uk) Спосіб лікування фето-плацентарної недостатності

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.